References
Swan SK, Hursting MJ (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318–329
Guzzi LM, McCollum DA, Hursting MJ (2006) Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 22:169–176
Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT (2005) Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39:231–236
Murray PT, Hursting MJ (2006) Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail 28:537–539
Beiderlinden M, Treschan TA, Gorlinger K, Peters J (2007) Argatroban anticoagulation in critically ill patients. Ann Pharmacother 41:749–754
Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY (2003) Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 37:652–654
Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G (2004) Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 24:409–414
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schusterschitz, N., Bellmann, R., Stein, M. et al. Influence of continuous veno-venous hemofiltration on argatroban clearance in a patient with septic shock. Intensive Care Med 34, 1350–1351 (2008). https://doi.org/10.1007/s00134-008-1039-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-008-1039-2